[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"insulin-sensitivityresistance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:insulin-sensitivityresistance":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,48,104,137,162,196,224,255,292,313,340,372,416],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100645002","phase-2-exercise-and-intranasal-insulin-in-type-2-diabetes-100645002",false,"NCT07675499","Exercise and Intranasal Insulin in Type 2 Diabetes","Effects of Intranasal Insulin Plus Exercise Training on Brain Blood Flow, Neuronal Insulin Signaling, and Cognition in Adults With Type 2 Diabetes","Inclusion Criteria:\n\n* Male or female 55-80 years old\n* Type 2 diabetes diagnosis or confirmation HbA1c \\>6.5% and fasting glucose \\>126 mg\u002Fdl\n* Individuals prescribed metformin, GLP-1 agonists (oral\u002Finjectable), TZDs, DPP-IV inhibitors, Acarbose, SGLT-2 inhibitors \\>6 months.\n* MOCA ≥26\n* Body mass index (BMI) ≥25 and ≤40 kg\u002Fm2\n* Not diagnosed with Type 1 diabetes\n* Not currently engaged in \\\u003C90 min\u002Fwk of exercise\n\nExclusion Criteria:\n\n* A diagnosis of dementia\n* Neurologic disease (e.g. Parkinson's, autonomic neuropathy, etc.)\n* Intolerance to insulin\n* Morbidly obese patients (BMI \\>40 kg\u002Fm2) and lean patients (BMI \\\u003C25 kg\u002Fm2)\n* \\>2 kg weight change in past 6 months\n* Participants who have been recently active (\\>90 min of moderate\u002Fhigh intensity exercise)\n* Individuals who are smokers or who have quit smoking (\\\u003C2 years)\n* Hypertriglyceridemia (400 mg\u002Fdl) and hypercholesterolemic (\\>260 mg\u002Fdl) subjects\n* Uncontrolled Hypertensive (\\>160\u002F100 mmHg)\n* Participants with a history of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures, or impact subject safety\n* Pregnant (as evidenced by positive pregnancy test) or nursing women\n* Participants with contraindications to participation in an exercise training program\n* Major psychiatric disorders (e.g. psychosis, bipolar disorder, major depression, alcohol\u002Fsubstance abuse)\n* History of head trauma or loss of consciousness in last 5 years.\n* Known contraindications for MR imaging:\n\n  * History of head trauma or neurosurgery, or neurological disorder (other than headaches or peripheral nerve disease) as these may impact neuroimaging results.\n  * Ferrous material implanted in or on the body, including flakes or filings, surgical clips, bullets, or electrical devices such as a pacemaker, or nonremovable ferrous jewelry (fillings in teeth and permanent retainers are permitted).\n  * Fillings and permanent retainers do not provide a safety risk and are not general exclusions. However, upper retainers may cause artifacts in ventral frontal regions and therefore may be an exclusion for some studies.\n  * Individuals with surgical pins or plates above the neck are excluded. Surgical pins or plates below the neck are exclusions, except when the material is fixed to bone, and considered acceptable by the Reference Manual for Magnetic Resonance Safety. Implants and Devices, 2020 Edition. Almost all recent orthopedic implants are made of materials that are not ferromagnetic and therefore are safe for scanning, and even though some screws are still made of ferromagnetic materials these are firmly screwed into bone. In cases where the material is unknown or deemed unsafe for scanning by the Reference Manual for Magnetic Resonance Safety. Implants and Devices the participant will be excluded.\n  * History of eye injury involving metallic materials, shavings in eyes, or welding without a face mask\n  * Lead\u002Firon tattoos\n  * Claustrophobia (history of significant anxiety in closed places).\n  * Back problem that would prevent the subject from laying still comfortably for up to 90 minutes.\n  * Deafness","ALL","55 Years","80 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","About 6.5 million adults in the United States who are 65 or older have dementia.\n\nWhile the exact cause of dementia is not known, it may be due to changes in the brain. Further, risk may be higher when the brain does not respond to insulin. Indeed, brain insulin resistance has emerged as a pathologic factor affecting memory, executive function as well as systemic glucose control. Regular aerobic exercise may help reduce the risk of dementia by increased blood flow to the brain and help the brain respond better to insulin. In addition, giving insulin through a nose spray (called intranasal insulin) may also help with thinking and memory. However, it is unknown if using both exercise and intranasal insulin is best for the brain.",[28,29,30,31],"Type 2 Diabetes","Insulin Sensitivity\u002FResistance","Cognition","Brain Blood Flow",[33,34],"Exericse","Intranasal Insulin","RECRUITING","2026-06-26",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":21},"2026-08-03",{"date":43,"type":21},"2029-05-31",{"name":45,"class":46},"Rutgers, The State University of New Jersey","OTHER",4,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":80,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100526751","effect-of-endoscopic-sleeve-gastroplasty-in-patients-with-obesity-and-mash-a-randomized-controlled-trial-100526751","NCT06138821","Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial","Effect of Endoscopic Sleeve Gastroplasty on Patients With Obesity and Concomitant Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Multicenter, Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 (male or female)\n2. BMI ≥30 kg\u002Fm2 or ≥27 kg\u002Fm2 with at least one obesity-related comorbidity\n3. Self-reported stable weight (no weight change \\>5%) for 6 months prior to the first study visit\n4. Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing laboratory\u002Fimaging\u002Fadditional tests, and completing diet counseling\n5. Willingness to NOT start a new anti-obesity medication for the following 12 months\n6. Residing within a reasonable distance from the investigator's office and able to travel to the investigator to complete routine follow-up visits\n7. Ability to give informed consent\n8. Women of childbearing potential (i.e., not post-menopausal, nor surgically sterilized) must agree to use adequate birth control methods\n\nExclusion Criteria:\n\n1. Known history of other chronic liver diseases (viral hepatitis, autoimmune hepatitis, drug-induced hepatitis, and genetic)\n2. Treatment with vitamin E (at doses ≥800 IU\u002Fday), pioglitazone, obeticholic acid, or resmetirom \\\u003C90 days before the first study visit\n3. History of foregut or gastrointestinal (GI) surgery (except uncomplicated fundoplication, cholecystectomy or appendectomy)\n4. Prior bariatric surgery\n5. Prior endoscopic sleeve gastroplasty\n6. Any inflammatory disease of the GI tract, including severe (LA Grade C or D) esophagitis, Barrett's esophagus with dysplasia, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease\n7. Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses\n8. Severe gastroesophageal reflux disease (GERD)\n9. A structural abnormality in the esophagus or pharynx, such as a stricture or diverticulum, that could impede passage of the endoscope.\n10. Achalasia or any other severe esophageal motility disorder\n11. Chronic abdominal pain\n12. Gastroparesis or intractable constipation\n13. Hepatic insufficiency or cirrhosis\n14. Severe coagulopathy\n15. Insulin-dependent diabetes (either type 1 or type 2) or a significant likelihood of requiring insulin treatment in the following 12 months or HgbA1C ≥ 12%\n16. Patients on an anti-platelet agent, anticoagulant agent or chronic\u002Froutine use of NSAIDs\n17. Patients on corticosteroids, immunosuppressants, or narcotics\n18. Patients on an anti-seizure or anti-arrhythmic medication\n19. Patients who are pregnant or breastfeeding\n20. Excessive alcohol consumption (\\>20 g per day for women; \\>30 g per day for men)\n21. Active smoking\n22. History of poorly controlled hypertension, coronary artery disease, congestive heart failure, cardiac arrhythmia\n23. History of respiratory diseases such as chronic obstructive pulmonary disease (COPD) requiring steroids, pneumonia, or cancer\n24. History of autoimmune connective tissue disorder such as lupus, scleroderma or immunocompromised disease\n25. History of active malignancy\n26. History of genetic or hormonal causes for obesity, such as Prader Willi syndrome\n27. History of endocrine disorders affecting weight, such as uncontrolled hypothyroidism\n28. Eating disorders, including night eating syndrome, bulimia, binge eating disorder or compulsive overeating\n29. Active psychological issues preventing participation in a lifestyle modification program as determined by a psychologist","18 Years",{"count":57,"type":21},132,[59],"NA","Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectrum, bariatric surgery has shown promise in the treatment of MASLD\u002Fmetabolic dysfunction-associated steatohepatitis (MASH) due to its efficacy in inducing weight loss. Nevertheless, its adoption has been hindered by the perceived invasiveness of surgery.\n\nOver the past decade, endoscopic sleeve gastroplasty (ESG) has gained recognition as a promising minimally-invasive approach to weight loss. The procedure involves utilizing a Food and Drug Administration (FDA)-authorized endoscopic suturing device to reduce the gastric volume by 70%. Studies reveal that ESG is associated with approximately 18.2% weight loss at one year after the procedure, with sustained results for at least 10 years. Nevertheless, the effect of ESG on MASH remains unknown.\n\nIn this study, the investigators will compare ESG + lifestyle modification versus lifestyle modification alone in treating histologic MASH. The study will randomize patients to one of two different treatment options: ESG + lifestyle modification or lifestyle modification alone.",[62,63,64,65,66,67,68,69,70,71,72,29,73,74,75,76,77,78,79],"Obesity","Liver Diseases","Liver Fibrosis","Liver Fat","Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Dysfunction-Associated Steatohepatitis","MASLD","MASH","Weight Loss","Insulin Resistance","Insulin Sensitivity","Metabolic Disease","Diabetes","Diabetes Mellitus, Type 2","NASH With Fibrosis","Non-Alcoholic Fatty Liver Disease","Non Alcoholic Fatty Liver","Non-alcoholic Steatohepatitis",[81,82,83,84,85,86,87,88,89,90,91,92,93],"Gut Hormones","Endoscopic Bariatric and Metabolic Therapy (EBMT)","Intragastric Balloon (IGB)","Endoscopic Suturing","Endoscopic Sleeve Gastroplasty (ESG)","Weight Management","Endoscopic Gastric Remodeling (EGR)","Endoscopic Bariatric Therapy (EBT)","Fatty Liver","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Non-Alcoholic Fatty Liver Disease (NAFLD)","Non-Alcoholic Steatohepatitis (NASH)","2026-06-23",{"date":96,"type":39},"2026-06-25",{"date":98,"type":39},"2025-06-24",{"date":100,"type":21},"2028-06",{"name":102,"class":46},"Pichamol Jirapinyo, MD, MPH",2,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":111,"sex":16,"minAge":55,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":121,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100643285","the-influence-of-obesity-and-insulin-sensitivity-on-reward-processing-and-decision-making-100643285","NCT07638059","The Influence of Obesity and Insulin Sensitivity on Reward Processing and Decision Making","No acronym","Inclusion Criteria:\n\n* 18 to 45 years of age\n* Self-reported weight stable (within 5 lbs) for previous 3 months\n* Not pregnant or planning to become pregnant during study participation\n* Weigh more than 110 lbs (due to blood draws used in study)\n* Residing in Roanoke, VA, area and\u002For willing to attend sessions at the Fralin Biomedical Research Institute\n\nExclusion criteria:\n\n* BMI \\\u003C 18.5 or \\> 40 kg\u002Fm2\n* Hemoglobin A1c \\> 6.4%\n* Fasting blood glucose \\> 126 mg\u002FdL\n* 2-hour blood glucose \\> 200 mg\u002FdL\n* Self-reported current diagnosis of diabetes or other endocrine\u002Fmetabolic disorder\n* Self-reported current inhaled nicotine use\n* Self-reported history of alcohol dependence\n* Self-reported use of medications known to influence study measures (including antiglycemic agents, thyroid medications, etc.)\n* Self-reported neurological or psychological disorder\n* Self-reported claustrophobia or discomfort with mock fMRI training\n* Self-reported history of head injury resulting in loss of consciousness for more than 10 minutes\n* Contraindications to MRI, including pacemaker, aneurysm clip, neurostimulator, cochlear implant, metal in eyes, steel worker, other implants\n* Self-reported previous metabolic\u002Fweight loss surgery\n* Self-reported adherence to special or restrictive diet within the past 3 months (e.g., low-carb, ketogenic, exclusion of food groups\u002Fspecific macronutrients, etc.)\n* Self-reported allergy to ingredient used in the study drinks",true,"45 Years",{"count":114,"type":21},50,[59],"Reward learning and decision-making processes, which operate largely outside of conscious control, shape food choices and eating behaviors. Excess adiposity is associated with differences in brain structure and functional connectivity underlying these processes, and insulin resistance, which commonly co-occurs with excess adiposity, has been linked with dopamine signaling that is crucial for these processes. However, whether and how excess adiposity and insulin resistance affect reward learning and decision-making remains poorly understood. This study will address that gap, examining the effects of excess adiposity and insulin resistance, and their interaction, on processes of reward learning and decision-making in food-specific and general contexts.",[118,29,119,120],"Adiposity","Decision-Making","Reward Learning",[122,123,124,125,126],"flavor nutrient learning","insulin sensitivity","adiposity","decision-making","probabilistic learning","NOT_YET_RECRUITING","2026-06-05",{"date":130,"type":39},"2026-06-10",{"date":132,"type":21},"2026-07-01",{"date":134,"type":21},"2029-07-01",{"name":136,"class":46},"Virginia Polytechnic Institute and State University",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":112,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100568993","high-intensity-interval-training-and-insulin-sensitivity-in-type-2-diabetes-100568993","NCT06688461","High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes","Effects of High Intensity Interval Training on Skeletal Muscle Insulin Sensitivity in Type 2 Diabetes Patients","T2D-HIIT","Inclusion Criteria:\n\n* Participants are able to provide signed and dated written informed consent prior to any study specific procedures\n* Aged ≥ 45 and ≤ 75 years\n* BMI: 25-35 kg\u002Fm2\n* Diagnosed as T2DM patients for at least 1 year and not longer than 5 years\n* HbA1c ≥ 6.5% and ≤ 8.5%\n* Fasting blood glucose \\\u003C130 mg\u002FdL\n* Women are post-menopausal (\\>1 year cessation of menses),\n* Being stable on medication use of metformin and\u002For sulfonylurea derivatives for the previous 3 months or more and other medication naïve.\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* Patients with congestive heart failure and and\u002For severe renal and or liver insufficiency\n* Contraindications for MRI\u002FMRS examination\n* Active diabetic foot\n* Polyneuropathy or retinopathy\n* Signs of active liver or kidney dysfunction\n* BMI \\>35 kg\u002Fm2\n* Exogeneous insulin therapy\n* Use of antidiabetic medication other than metformin or sulfonylurea derivatives treatment within 3 months before screening\n* Use of SGLT2 inhibitors\n* Unstable body weight (variations \\>5kg in the last 3 months)\n* Ongoing weight loss diet or use of weight loss agents\n* Uncontrolled hypertension\n* Engagement in regular exercise program or any other medical condition that will impede the safe performance of the experiments","75 Years",{"count":147,"type":21},36,[59],"A recognized driver for cardiovascular complications of type 2 diabetes mellitus (T2DM) is impaired plasma glucose homeostasis as consequence of skeletal muscle insulin resistance. Insulin-mediated plasma glucose disposal in skeletal muscle comprises oxidative glucose disposal (cellular glucose uptake for oxidation) and non-oxidative glucose disposal (NOGD; cellular glucose uptake for storage as glycogen), both processes being impaired in T2DM patients. Excessive intrahepatic fat accumulation (particularly monounsaturated (MUFA) and saturated (SFA)) is commonly observed in T2DM patients and tightly associates with plasma glucose dysregulation. It has been hypothesized that skeletal muscle insulin resistance redistributes circulating glucose away from muscle which together with hyperinsulinemia promotes intrahepatic lipid accretion via de novo lipogenesis (DNL). As saturated lipids is the final product of DNL, improving skeletal muscle insulin sensitivity, next to enhance plasma glucose homeostasis, might lower intrahepatic lipid content particularly intrahepatic saturated lipids.\n\nRegular exercise is a cornerstone in the treatment of T2DM and to improve skeletal muscle insulin sensitivity. Interestingly, a conventional exercise program (aerobic-type combined with strength-type exercise) restores insulin-stimulated oxidative glucose disposal in T2DM patients to levels observed in age-matched normoglycemic subjects. Non-oxidative glucose disposal (NOGD), however, does not improve upon such conventional exercise programs. In this regard, for full restoration of compromised glucose disposal, it is pivotal to come up with effective training methods to target NOGD. High intensity interval training (HIIT) has the potential to expands the glycogen synthesis capacity in athletes by repetitive cycles of glycogen depletion\u002Frepletion, hence holds promise to improve NOGD in T2DM patients. Of note, HIIT also lowers the intrahepatic fat content in pre-diabetes individuals. Nevertheless, whether HIIT reduces the intrahepatic fat content and modifies its composition in T2DM patients is unknown. In this regard, it is hypothesized that HIIT expands the NOGD capacity in skeletal muscle of overweight\u002Fobese type 2 diabetes patients. By doing so, it is postulated that HIIT improves skeletal muscle insulin sensitivity and therefore benefits the 24 hours glycaemic profile in T2DM patients. In line, it is hypothesized that the HIIT-mediated improvements on NOGD and skeletal muscle insulin sensitivity coexist with the reduction of intrahepatic lipid content -particularly reduced saturated lipids- via lowering DNL.",[28,151,29],"Lifestyle-related Condition","2026-03-13",{"date":154,"type":39},"2026-03-16",{"date":156,"type":39},"2024-10-01",{"date":158,"type":21},"2026-12-31",{"name":160,"class":46},"Finis Terrae University",1,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":111,"sex":16,"minAge":112,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":177,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":161},"100399795","targeting-risk-factors-for-diabetes-in-subjects-with-normal-blood-cholesterol-using-omega-3-fatty-acids-100399795","NCT04485871","Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids","White Adipose Tissue LDL Receptors and Omega-3 as Modulators of the Risk for Type 2 Diabetes in Subjects With Normal Plasma LDL Cholesterol","Inclusion Criteria:\n\nMen and post-menopausal women:\n\n* Having a body mass index (BMI= 25-40 kg\u002Fm2)\n* Aged between 45 and 74 years\n* Having confirmed menopausal status (FSH ≥ 30 U\u002Fl)\n* Non-smoker\n* Sedentary (less than 2 hours of structured physical exercise (ex: sports club) per week)\n* Low alcohol consumption: less than 2 alcoholic drinks\u002Fday\n\nExclusion Criteria:\n\n* Plasma LDL cholesterol \\> 3.5 mmol\u002FL (i.e. \\> 75th percentile in a Canadian population).\n* Elevated risk of cardiovascular disease (≥ 20% of calculated Framingham Risk Score) who would require immediate medical intervention by lipid-lowering agents.\n* Prior history of cardiovascular events (like stroke, transient ischemic attack, myocardial infarction, angina, heart failure…)\n* Systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\> 90 mmHg\n* Type 1 or 2 diabetes or fasting glucose \\> 7.0 mmol\u002FL\n* Prior history of cancer within the last 3 years\n* Thyroid disease - untreated or unstable\n* Anemia - Hb \\\u003C 120 g\u002FL\n* Renal dysfunction or plasma creatinine \\> 100 µmol\u002FL\n* Hepatic dysfunction - AST\u002FALT \\> 3 times normal limit\n* Blood coagulation problems (i.e. bleeding predisposition)\n* Autoimmune and chronic inflammatory disease (i.e. celiac, inflammatory bowel, Graves, multiple sclerosis, psoriasis, rheumatoid arthritis, and lupus).Known history of difficulties accessing a vein\n* Claustrophobia\n* Sleep apnea\n* Seizures\n* Concomitant medications: Hormone replacement therapy (except thyroid hormone at a stable dose), systemic corticosteroids, anti-psychotic medications and psycho-active medication, anticoagulant or anti-aggregates treatment (Aspirin, NSAIDs, warfarin, coumadin..), adrenergic agonist, anti-hypertensive drugs, weight-loss medication, lipid lowering medication\n* Known substance abuse\n* Already taking more than 250 mg of omega-3 supplements (EPA\u002FDHA) per day\n* Allergy to seafood or fish\n* Allergy to Xylocaine\n* Unable to eat the components of the high fat meal (croissant, cheese, bacon, brownies)\n* None compliance to the study requirements (i.e. not being fasting) or cancellation of the same scheduled testing visit more than once.\n* Lack of time to participate in the full length of the study (33 weeks)\n* Have exceeded the annual total allowed radiation dose (like X-ray scans and\u002For tomography in the previous year or in the year to come) according to the physician's judgement.\n* All other medical or psychological conditions deemed inappropriate according to the physician","74 Years",{"count":171,"type":21},48,[59],"Every 3 minutes a new case of diabetes is diagnosed in Canada, mostly type 2 diabetes (T2D) increasing the risk for heart disease. T2D and heart disease share many common risk factors such as aging, obesity and unhealthy lifestyle.\n\nParadoxically however, while lowering blood LDL, commonly known as \"bad cholesterol\", is protective against heart disease, research over the past 10 years have shown that the lower is blood LDL, the higher is the chance of developing T2D. This phenomena is happening whether blood LDL is lowered by a common drug against heart disease called Statins, or by being born with certain variations in genes, some of which are very common (\\~80% of people have them).\n\nTo date, it is unclear why lowering blood LDL is associated with higher risk for diabetes, and whether this can be treated naturally with certain nutrients.\n\nInvestigators believe that lowering blood LDL by forcing LDL entry into the body tissue through their receptors promotes T2D. This is because investigators have shown that LDL entry into human fat tissue induces fat tissue dysfunction, which would promote T2D especially in subjects with excess weight.\n\nOn the other hand, investigators have shown that omega-3 fatty acids (omega-3) can directly treat the same defects induced by LDL entry into fat tissue. Omega-3 is a unique type of fat that is found mostly in fish oil.\n\nThus the objectives of this clinical trial to be conducted in 48 subjects with normal blood LDL are to explore if:\n\n1. Subjects with higher LDL receptors and LDL entry into fat tissue have higher risk factors for T2D compared to subjects with lower LDL receptors and LDL entry into fat tissue\n2. 6-month supplementation of omega-3 from fish oil can treat subjects with higher LDL receptors and LDL entry into fat tissue reducing their risk for T2D.\n\nThis study will thus explore and attempt to treat a new risk factor for T2D using an inexpensive and widely accessible nutraceutical, which would aid in preventing T2D in humans.",[28,175,29,176],"Inflammation","Fatty Acids, Omega-3",[178,179,180,181,182,183,184,185,186],"Proprotein Convertase Subtilisin \u002F kexin Type 9 (PCSK9)","NLRP3 inflammasome","Eicosapentaenoic acid (EPA)","Docosahexaenoic acid (DHA)","White adipose tissue","Fat metabolism","ApoB-lipoproteins","LDL receptors (LDLR)","Cluster of differentiation 36 (CD36)","2026-03-11",{"date":189,"type":39},"2026-03-12",{"date":191,"type":39},"2019-12-19",{"date":193,"type":21},"2027-05-31",{"name":195,"class":46},"Institut de Recherches Cliniques de Montreal",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":111,"sex":16,"minAge":55,"maxAge":18,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":212,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":161},"100540754","phase-2-vital-impact-improving-cardiometabolic-health-in-black-individuals-through-therapeutic-augmentation-of-cyclic-guanosine-mono-phosphate-signaling-pathway-100540754","NCT06320951","VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway","Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway","VITAL-IMPACT","Inclusion Criteria:\n\n* Adults: Age more than or equal to 18 years of age\n* Self-identified race\u002Fethnicity as African-American or Black\n* BMI ≥ 30 kg\u002Fm2\n* HOMA-IR ≥ 2.5\n* Blood pressure: 120-160\u002F80-100 mmHg (untreated or 1 week of washout in those treated with up to two classes of antihypertensives)\n* Willing to adhere to study protocol\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence)\n* Have any past or present history of cardiovascular diseases (stroke, myocardial infarction, heart failure, transient ischemic attack, angina, seizure or cardiac arrhythmia)\n* BP more than 160\u002F100 mmHg or those treated with three or more classes of antihypertensives\n* BMI \\>45 kg\u002Fm2\n* History of diabetes or fasting plasma glucose \\>=126 mg\u002FdL or HbA1C\\>=6.5% or prior treatment with antidiabetics\n* Estimated GFR \\\u003C 60 ml\u002Fmin\u002F1.73 m2; albumin-creatinine ratio ≥30 mg\u002Fg\n* Hepatic Transaminase (AST and ALT) levels \\>3x the upper limit of normal\n* Significant psychiatric illness (assessed using validated MINI questionnaire)\n* Anemia (men, Hb\\\u003C13 g\u002FdL; women, Hb \\\u003C12 g\u002FdL)\n* Inability to exercise on a treadmill",{"count":205,"type":21},200,[24],"This study investigates the potential of vericiguat, a soluble guanylate cyclase stimulator, to improve cardiometabolic health in obese Black individuals with insulin resistance by directly enhancing cyclic guanosine monophosphate (cGMP) activity. Given that this population has been shown to have lower cGMP activity and the association of lower cGMP activity with increased cardiometabolic disease risk, the proposed study hypothesizes that augmenting cGMP activity in obese individuals will improve insulin sensitivity and energy expenditure. This study is a placebo-controlled randomized trial involving 200 Black obese participants with insulin resistance, assessing the effects of vericiguat on insulin sensitivity, resting, and exercise-induced energy expenditure over 12 weeks. Additionally, it will explore changes in brown adipose tissue and gene expression related to energy metabolism in white adipose tissue, aiming to provide insights into how increasing cGMP activity may improve cardiometabolic health in Black obese individuals.",[209,29,73,210,211,62],"Cardiovascular Diseases","Metabolism","Energy Expenditure",[211,72,213,214],"African Americans","Cyclic Guanosine Monophosphate","2026-01-21",{"date":217,"type":39},"2026-01-23",{"date":219,"type":21},"2026-12-01",{"date":221,"type":21},"2029-04-30",{"name":223,"class":46},"University of Alabama at Birmingham",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":111,"sex":16,"minAge":232,"maxAge":17,"enrollmentInfo":233,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":236,"conditions":237,"keywords":239,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":251,"leadSponsor":253,"locationsCount":161},"100612609","defining-the-human-insulin-resistance-molecular-network-signature-100612609","NCT07255807","Defining the Human Insulin Resistance Molecular Network; SIGNATURE","sIgnatuRe: Defining the Human Insulin Resistance Molecular Network","SIGNATURE","Inclusion Criteria:\n\n* Age: 25-55 years\n* Body Mass Index (BMI): 18-30 kg\u002Fm²\n* Healthy (no diagnosed chronic diseases)\n* Able and willing to comply with study procedures\n\nExclusion Criteria:\n\n* Smoking or nicotine use, current or within the past 5 years\n* Alcohol intake exceeding 10 units per week\n* Hemoglobin A1c (HbA1c) \\> 48 mmol\u002Fmol (indicative of diabetes or prediabetes)\n* Chronic diseases (e.g., cardiovascular disease, diabetes, etc.)\n* Chronic medication use, including hormonal treatments\n* High physical activity levels (more than 3 hours per week of moderate to vigorous exercise)\n* Pregnancy or within 3 months postpartum\n* Breastfeeding or within 3 months of cessation\n* Abnormal routine blood markers (as defined in lab screening)\n* Blood donation within the past 2 months","25 Years",{"count":234,"type":21},80,[59],"The goal of this intervention study is to learn more about what causes insulin resistance in otherwise healthy adults, and how short-term changes in physical activity or diet may influence it. The study includes healthy male and female participants aged 25 to 55 years, who meet specific health criteria.\n\nThe main questions it aims to answer are:\n\nDoes the cause of insulin resistance vary between individuals due to their genes and lifestyle?\n\nCan the investigators identify different types (sub-phenotypes) of insulin resistance at the molecular level?\n\nResearchers will compare groups who either reduce their physical activity for 14 days or consume a high-fat diet for 3 days, to see how these changes affect insulin sensitivity and related biological markers.\n\nParticipants will:\n\n* Complete a health screening and be assessed for eligibility\n* Undergo baseline testing to measure insulin sensitivity, physical activity, diet, and metabolic health\n* Be randomly assigned to one of two short-term interventions (14 days of reduced physical activity, or 3 days of a high-fat, high-calorie diet)\n* Repeat selected tests after the intervention to assess changes\n\nThis study will help researchers better understand how lifestyle and biology interact in the development of insulin resistance, even in people who are otherwise healthy.",[238,29],"Metabolic Health",[71,238,240,241,242,243,244,72,245,246],"Glucose Metabolism","Lifestyle Interventions","Physical Inactivity","High-Fat Diet","Molecular Mechanisms","Metabolic Phenotyping","Human Intervention Study","2025-11-20",{"date":249,"type":39},"2025-12-01",{"date":249,"type":21},{"date":252,"type":21},"2038-06-30",{"name":254,"class":46},"University of Copenhagen",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":275,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":290,"locationsCount":161},"100585948","phase-3-semaglutide-treatment-in-type-1-diabetes-100585948","NCT06909006","Semaglutide Treatment in Type 1 Diabetes","Obesity and Semaglutide in Type 1 Diabetes Therapy: A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial","OBES1TY","Inclusion Criteria:\n\n* Type 1 Diabetes for more than 3 years\n* BMI ≥ 30 or ≥ 27 and atleast one comorbidity (hypertension, hypercholesterolemia, microalbuminuria, ischemic heart disease, history of stroke, atherosclerosis or arthrosis\n\nExclusion Criteria:\n\n* Treated with GLP1-RAs within last 6 months\n* Known intolerance for semaglutide\n* Other forms of diabetes\n* Pregnant or nursing women\n* Fertile women not using chemical (hormonal) or mechanical (spiral) contraceptives\n* Liver disease with elevated plasma alanine aminotransferase (ALT) \\> five times and plasma aspartate aminotransferase (AST) \\> five times the upper limit of normal (measured at visit 0 with the possibility of one repeat analysis within a week, and the last measured value as being conclusive)\n* Acute or chronic pancreatitis\n* Cancer, unless in complete remission for \\> 5 years or unless basocellular carcinomas\n* History of thyroid adenoma or carcinoma\n* Alcohol\u002Fdrug abuse\n* Other concomitant disease or treatment that according to the investigator's assessment makes the patient unsuitable for study participation\n* Receipt of an investigational drug within 30 days prior to visit 0 \u002F Simultaneous participation in any other clinical intervention trial",{"count":264,"type":21},122,[25],"The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.",[268,269,270,29,271,272,273,70,274],"Obesity in Diabetes","Obesity\u002FTherapy","Type 1 Diabetes Mellitus (T1DM)","Semaglutide","Lipidomics","Metabolomics","Glycemic Control for Diabetes Mellitus",[271,62,276,277,278,279,280,281,282,283],"Type 1 Diabetes","Obese Type 1 Diabetics","Insulin sensitivity","Insulin resistance","Weight loss","GLP1-RA","GLP1","Wegovy","2025-08-04",{"date":286,"type":39},"2025-08-08",{"date":288,"type":21},"2025-10",{"date":100,"type":21},{"name":291,"class":46},"Nordsjaellands Hospital",{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":111,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":301,"conditions":302,"keywords":305,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":312,"locationsCount":161},"100366758","phase-2-nautical-effect-of-natriuretic-peptide-augmentation-on-cardiometabolic-health-in-black-individuals-100366758","NCT04055428","NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals","The Effects of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals (NAUTICAL)","Inclusion Criteria:\n\n* Adults: Age more than or equal to 18 years of age\n* Self-identified race\u002Fethnicity as African-American or Black\n* Blood pressure: 120-160\u002F80-100 mmHg\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence)\n* Have any past or present history of cardiovascular diseases (stroke, myocardial infarction, heart failure, transient ischemic attack, angina, or cardiac arrhythmia)\n* BP more than 160\u002F100 mmHg\n* BMI \\>45 kg\u002Fm2\n* History of diabetes or fasting plasma glucose \\>=126 mg\u002FdL or HbA1C\\>=6.5%\n* History of angioedema\n* Current or past (\\\u003C12 months) history of smoking\n* Estimated GFR \\\u003C 60 ml\u002Fmin\u002F1.73 m2; albumin-creatinine ratio ≥30 mg\u002Fg\n* Hepatic Transaminase (AST and ALT) levels \\>3x the upper limit of normal\n* Significant psychiatric illness or seizure disorder\n* More than 2 Alcoholic drinks daily\n* Anemia (men, Hct \\\u003C 38%, Hb\\\u003C13 g\u002FdL; women, Hct \\\u003C36%, Hb \\\u003C12 g\u002FdL)\n* Inability to exercise on a treadmill",{"count":205,"type":21},[24],"Black individuals are more likely to have decreased insulin sensitivity which results in a high risk for the development of cardiometabolic disease. The reasons for this are incompletely understood. Natriuretic peptides (NPs) are hormones produced by the heart that play a role in regulating the metabolic health of an individual. Low circulating level of NPs is an important contributor to increased risk for diabetes. The NP levels are relatively lower among Black individuals thus affecting their metabolic health and putting them at a higher risk for diabetes. This study aims to test the hypothesis that by augmenting NP levels using sacubitril\u002Fvalsartan, among Black Individuals one can improve their metabolic health (as measured by insulin sensitivity \\& energy expenditure) and help establish the role of NPs in the underlying mechanism behind increased risk for cardiometabolic disease in these population.",[303,209,29,73,304,210,211],"Diabetes Mellitus","Natriuretic Peptides",[304,74,72,211],"2025-07-01",{"date":308,"type":39},"2025-07-03",{"date":310,"type":39},"2020-08-15",{"date":193,"type":21},{"name":223,"class":46},{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":320,"minAge":321,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":325,"phases":4,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":161},"100399528","puberty-suppression-and-cardiometabolic-health-100399528","NCT04482374","Puberty Suppression and Cardiometabolic Health","Effects of Puberty and Pubertal Suppression on Insulin Sensitivity, Metabolic Rate and Vascular Health","Inclusion Criteria:\n\n* Identify as a transgender female or cisgender male\n* Age 9-14 years at the time of enrollment\n* Tanner Stage 2-3 baseline pubertal development\n* Plan to start gonadotropin releasing hormone analogue clinically in \\\u003C 2 months (for transgender females only)\n\nExclusion Criteria:\n\n* Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the study procedures\n* Type 1 or 2 diabetes (by medical history)\n* On any medications that affect insulin sensitivity (e.g. metformin, antipsychotics)\n* Hypertension (resting BP ≥ 140\u002F90 mm\u002FHg)\n* Weight \\> 400 lbs\n* On estrogen- or progesterone-containing medications at baseline\n* \\>3 hours of moderate-to-vigorous physical activity on the 3DPAR at the screening visit","MALE","9 Years","14 Years",{"count":324,"type":21},30,"OBSERVATIONAL","This observational study will evaluate the effect of puberty suppression on insulin sensitivity, metabolic rate and vascular health among transgender female youth at baseline and 6 months after initiation of a gondoatropin releasing hormone agonist compared to matched cisgender male controls.",[328,29,329,330],"Transgenderism","Endothelial Dysfunction","Vascular Stiffness","2025-06-05",{"date":333,"type":39},"2025-06-10",{"date":335,"type":39},"2020-08-10",{"date":337,"type":21},"2026-07-31",{"name":339,"class":46},"University of Colorado, Denver",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":325,"phases":4,"briefSummary":351,"conditions":352,"keywords":355,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":161},"100581898","response-to-semaglutide-in-non-diabetic-obese-patients-with-varying-degrees-of-insulin-resistance-100581898","NCT06856291","Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance","Treatment Response to Incretin Mimetics in Non-diabetic Obese Patients With and Without Insulin Resistance (TRIM-IR)","TRIM-IR","Inclusion Criteria:\n\n1. Age between 18 and 60 years\n2. BMI 30 - 40 kg\u002Fm2\n\n   a. Participants must meet the eligibility criteria for coverage under the KVG (Federal Health Insurance Act) and the Specialties List, which include a weight-related comorbidity (arterial hypertension, dyslipidemia) for participants with a BMI of 30- 35 kg\u002Fm2\n3. Planned therapy with semaglutide as a weight loss intervention\n4. No known presence of a diabetic state\n5. Ability to understand and sign a Patient Information and Consent Form\n\nExclusion Criteria:\n\n1. Pregnancy or active breast feeding\n\n   1. Therapy with semaglutide is not approved for use during pregnancy or while breastfeeding, as its safety and efficacy in these conditions have not been established.\n   2. Pregnancy is an exclusion criterion for the planned investigations to avoid placing pregnant individuals under unnecessary physical or psychological stress that could pose risks to both the individual and the fetus.\n2. Medication and\u002For pathologies that prevent the safe execution of the fat tissue biopsies (e.g. allergy towards local anesthetics, disorders of coagulation, treatment with anticoagulants)\n3. Medical conditions that prevent examinations and testing (e.g. epilepsia, symptomatic cardiovascular disease)\n4. History of or planned bariatric surgery\n5. HbA1c ≥ 6.5% as measured by the central laboratory at screening\n6. Fasting plasma-glucose \\>7.0 mmol\u002Fl\n7. History of type 1 or type 2 diabetes mellitus\n8. Treatment with glucose-lowering agent(s) (e.g. Metformin) within 90 days before screening\n9. Treatment with a GLP-1 (glucagon like peptide 1) receptor agonist within 180 days before screening\n10. A self-reported change in body weight \\>5% within 90 days before screening\n11. Active malignancy (\\\u003C2a since remission)\n12. Treatment with any medication for the indication of obesity within the past 90 days before screening\n13. Uncontrolled thyroid disease, defined as thyroid stimulating hormone (TSH) \\> 10 mIU\u002FL or \\\u003C 0.4 mIU\u002FL as measured by the central laboratory at screening","60 Years",{"count":350,"type":21},40,"Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile. As the most commonly prescribed drug in this class, semaglutide is effective in both diabetic and non-diabetic individuals. However, treatment responses vary significantly, with non-diabetic individuals typically experiencing better weight loss outcomes. Despite this, up to 10% of non-diabetic individuals show little or no response to treatment, and the reasons for this variability remain unclear.\n\nThe TRIM-IR study aims to investigate the role of insulin resistance (IR) in weight loss outcomes among non-diabetic obese individuals receiving semaglutide. This single-center, observational study will assess the impact of IR on weight loss, body composition, and adipose tissue function during the first 16 weeks of semaglutide therapy. The study will also explore molecular markers of adipose tissue dysfunction, focusing on the transition from dysfunctional to healthy adipose tissue.\n\nThe investigators hypothesize, that individuals with lower IR will experience greater weight loss than those with higher IR, and that the glucose infusion rate (GIR) during hyperinsulinemic euglycemic clamp testing will correlate with weight loss variability. Secondary objectives include comparing changes in fat and lean mass, reductions in visceral fat, and improvements in adipose tissue function before and after 16 weeks of treatment. Exploratory analyses will assess adipocyte subpopulations and their response to insulin sensitivity changes.\n\nA total of 40 participants, equally distributed by gender, will be enrolled to ensure statistical power for detecting clinically relevant differences. The study aims to optimize semaglutide use for personalized obesity treatment and provide insights into the relationship between obesity, insulin resistance, and adipose tissue plasticity, with implications for improving obesity management and cardiovascular health outcomes.",[353,354,29,271],"Obesity and Obesity-related Medical Conditions","Obesity and Overweight",[71,356,357,358,359,360,361,362,123],"incretin mimetics","semaglutide","weight loss","adipose tissue function","obesity","hyperinsulinemic euglycemic clamp","obesity management","2025-03-24",{"date":365,"type":39},"2025-03-25",{"date":367,"type":39},"2025-03-15",{"date":369,"type":21},"2026-08-31",{"name":371,"class":46},"ETH Zurich",{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":16,"minAge":379,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":325,"phases":4,"briefSummary":382,"conditions":383,"keywords":399,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":161},"100569420","osaka-cardiometabolic-epidemiological-study-ohtori-study-part-2-100569420","NCT06694012","Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2","OCES-2","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n* Women who may be pregnant","20 Years",{"count":381,"type":21},2000,"The aim of this study is to investigate the relationship between body fat distribution measured by CT scan and related risk factors with the risk of incident metabolic and cardiovascular disease in a prospective cohort study of Japanese men and women. The investigators will also investigate novel risk factors for metabolic and cardiovascular disease using molecular weight-based metallomics analysis.",[384,28,303,385,386,387,388,389,390,62,391,392,393,394,395,396,397,398,29],"Type 2 Diabetes Mellitus (T2DM)","Hypertension","Hyperglycemia","Hyperlipidemia","Dyslipidemia","Hyperuricemia or Gout","Hyperuricemia, Gout","Obesity\u002FEpidemiology","Obesity, Abdominal","Central Obesity","Visceral Fat","Chronic Kidney Disease(CKD)","Atherosclerosis","Metabolic Syndrome","Hepatic Steatosis",[400,385,387,388,401,360,402,403,404,405,406,397,72,71],"Type 2 Diabetes Mellitus","Hyperuricemia","Abdominal obesity","Visceral fat","Visceral adiposity","Chronic Kidney Disease","Japanese","2024-11-29",{"date":409,"type":39},"2024-12-04",{"date":411,"type":39},"2024-11-01",{"date":413,"type":21},"2050-03-31",{"name":415,"class":46},"Osaka Metropolitan University",{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":111,"sex":423,"minAge":379,"maxAge":112,"enrollmentInfo":424,"targetDuration":4,"studyType":22,"phases":426,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":161},"100440058","insulin-sensitivity-after-breast-cancer-100440058","NCT05010356","Insulin Sensitivity After Breast Cancer","Study of Molecular Causes of Metabolic Disorders in Obese Premenopausal Women After Breast Cancer","Inclusion Criteria:\n\n* Premenopausal women operated for breast cancer and after completing adjuvant chemotherapy and no earlier than 3 weeks after its termination\n* BMI: 25-30\n* Healthy controls will be included matched by gender, weight, age, and level of physical activity to the patient group included as subjects\n\nExclusion Criteria:\n\n* Known postmenopause occurred at the time of diagnosis of breast cancer\n* Alcohol intake of\\> 7 items \u002F week\n* Smoker\n* Already known Type 2 diabetes mellitus or metabolic syndrome and medical treatment thereof.\n* Cardiovascular disease and its medical treatment\n* Impaired mobility","FEMALE",{"count":425,"type":21},24,[59],"Epidemiological studies have revealed that 60-80% of women with breast cancer (BC) develop metabolic disorders that are similar to those observed in conditions like type 2 diabetes. These metabolic disorders, including insulin resistance, obesity, hyperinsulinemia, and glucose intolerance, are associated with increased BC recurrence and mortality. Skeletal muscle is the major site of glucose uptake in humans. The aims of the present project are to 1) determine the involvement of insulin resistance in skeletal muscle in the metabolic disorders prevalent in BC survivors, 2) identify BC-and\u002For treatment-induced molecular changes in skeletal muscle from BC survivors .",[29,429,430,431],"Breast Cancer","Survivorship","Metabolic Disturbance","2021-08-10",{"date":434,"type":39},"2021-08-18",{"date":436,"type":21},"2021-08",{"date":438,"type":21},"2026-09",{"name":254,"class":46}]